Speaker illustration

Professor Yong Huo

Peking University First Hospital, Beijing (China)

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Cardiovascular Pharmacotherapy

Session: Pharmacology and Pharmacotherapy ePosters

Thumbnail

Stroke prevention from lifestyle to intervention

Event: ESC CONGRESS 2017

Topic: Treatment of hypertension

Session: Heart and brain interaction

Thumbnail

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Event: ESC Asia with APSC & AFC 2020

Topic: Cardiovascular Pharmacotherapy

Session: Abstract Programme

Thumbnail

This platform is supported by

logo Novo Nordisk